Drug Trial Radar · NCT05003713
Single and Multiple Ascending Dose Study of CORT125236 in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Mar 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
82
Actual
Start
Aug 3, 2021
Primary completion
Feb 3, 2023
Study completion Feb 3, 2023
Sponsor
- Lead sponsor
- Corcept TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Aug 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a 3-part, first-in-human study of single ascending doses (SAD; Part 1) and multiple ascending doses (MAD; Part 2) of CORT125236 in healthy participants; Part 3 is optional, to investigate whether CORT125236 ameliorates the effects of prednisone on various pharmacodynamic (PD) endpoints. The 3 parts may not be conducted entirely sequentially provided that this is justified by the pharmacokinetic (PK) and safety data obtained from completed cohorts. The first MAD cohort will not start until data are available from at least 3 SAD levels to allow MAD administration to proceed. The decision on whether to start Part 3 can be made at any point after completion of 3 SAD levels, and will be based on achieving sufficiently high plasma CORT125236 exposure in Part 1 of the study.
Conditions
- Healthy
Interventions
CORT125236Drug
CORT125236 Lipid Capsule Formulation 10-60 mg for oral administration
Placebo matching CORT125236Drug
Placebo matching CORT125236 Lipid Capsule Formulation 10-60 mg for oral administration
PrednisoneDrug
Prednisone tablet 25 mg (20 mg + 5 mg tablets) for oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with One or More Adverse EventsTime frame: Part 1 SAD Cohorts: up to Day 12; Part 2 MAD Cohorts: up to Day 25; Part 3 Cohort: up to Day 19
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site 01
Ruddington, Nottingham, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.